What development phase is AZAPERONE in?

AZAPERONE is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

AZAPERONE

FDA-approved active Small molecule Quality 10/100

At a glance

Generic name	AZAPERONE
Target	D(4) dopamine receptor, Transmembrane protein 97, 5-hydroxytryptamine receptor 1A
Modality	Small molecule
Therapeutic area	Neuroscience
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Premedication With Melatonin and Alprazolam Combination Versus Alprazolam or Melatonin Alone (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

AZAPERONE CI brief — competitive landscape report
AZAPERONE updates RSS · CI watch RSS